survival | malecare.org

Radioligand Therapy With 177Lu-PSMA-617 – A Novel Therapeutic Possibility on the Horizon in Men With Metastatic Castration Resistant Prostate Cancer.

We are seeing more and more novel therapies being developed to treat castrate resistant metastatic prostate cancer (mCRPC). One such therapy involves theranostic (individualized therapies for various diseases, and to combine diagnostic and therapeutic capabilities into a single agent) concepts using radiolabeled ligands of the prostate-specific membrane antigen (PSMA). In a recent study, designed to [...]

By Malecare|2016-04-28T16:08:19-04:00April 28th, 2016|Advanced Prostate Cancer, Clinical Trials & Research, Drugs & Treatments, On The Horizon, survival, Survival, Uncategorized|2 Comments

A new Trend – Chemotherapy for Metastatic Castrate-Sensitive Prostate Cancer

Prostate cancer treatment will change as we incorporate new studies into our clinical practice. One of the major emerging new trends is the earlier use of chemotherapy with androgen therapy (ADT) in men, including men who are still hormone responsive. This changing trend comes from the results from there pivotal randomized phase III trials: GETUG15, [...]

By Malecare|2017-10-19T10:46:35-04:00March 30th, 2016|Advanced Prostate Cancer, Chemotherapy, Clinical Trials, Clinical Trials & Research, docetaxel, Drugs & Treatments, Hormone Therapy, survival, Uncategorized, Understanding APC|0 Comments

PSA Decline After 4 Weeks of Abiraterone Suggests Overall Survival in Men with Metastatic Castration-Resistant Prostate Cancer

Since we have many new treatments for men with castrate resistant metastatic prostate cancer (mCRPC) (advanced prostate cancer) we need to develop earlier indicators of when a treatment might or might not be successful. A decline in prostate-specific antigen (PSA) is widely used to monitor treatment response, but it has not been validated as an [...]

By Malecare|2016-03-15T23:25:25-04:00March 15th, 2016|abiraterone acetate, Advanced Prostate Cancer, biomarkers, Clinical Trials & Research, Drugs & Treatments, PSA, Survival, survival, Uncategorized, Understanding Advanced Prostate Cancer, United Kingdom - England, Northern Ireland, Scotland & Wales, Zytiga|1 Comment

Can Radiotherapy (Radiation) for the Primary Tumors Benefit Men With Prostate CancerWith Distant Metastasis at Initial Diagnosis?

The common belief is that if you are diagnosed with prostate cancer that has already developed metastases only a systemic treatment will provide a life extending benefit. In other cancers it has been shown that the treatment of the primary tumor improves survival (tumor debulking). To find out if, in fact radiotherapy treatment of the [...]

By Malecare|2016-01-28T11:22:12-05:00January 28th, 2016|Advanced Prostate Cancer, Bio Chemical Recurrence, Bone Metastases, Drugs & Treatments, General Information, Radiotherapy, survival, Uncategorized, Understanding Advanced Prostate Cancer|0 Comments

Analyzing the Analysis – Is Surgery Superior to Radiotherapy? No, Despite the Results from A Large Canadian Study

It is a little out of the normal scope of this blog, but a recent prostate cancer study from Canada has received a lot of buzz and needs some commentary and analysis. The study concluded that for men who are diagnosed with local prostate cancer (still confined in the gland) live longer if they have [...]

By Malecare|2020-02-04T11:37:48-05:00December 23rd, 2015|Advanced Prostate Cancer, Canada, General Information, Localized Prostate Cancer, Radiotherapy, Research, Surgery, survival, Survival, Uncategorized|0 Comments